News | ECG Wireless Remote Access | May 04, 2020

Cardiac Insight Launches New Telehealth Solution for Cardiology Practices with [email protected] ECG Test Kit

Direct-to-patient Cardea Solo wearable ECG speeds clinical decision-making while removing costly and time-consuming outsourcing of data analysis 

Cardiac Insight's Heart@Home ECG Test Kit can help address new telehealth demands placed on cardiology practices by the COVID-19 response using arrhythmia diagnosis technology of the wearable Cardea Solo Sensor.

Cardiac Insight's [email protected] ECG Test Kit can help address new telehealth demands placed on cardiology practices by the COVID-19 response using arrhythmia diagnosis technology of the wearable Cardea Solo Sensor. 


May 4, 2020 — Cardiac Insight Inc., a U.S.-based digital healthcare innovator specializing in body-worn sensor technology and automated electrocardiogram (ECG)-analysis software, announced the [email protected] ECG Test Kit can help address new telehealth demands placed on cardiology practices by the COVID-19 response.

The kit enables physicians to prescribe the proven arrhythmia diagnosis technology of the Cardea Solo Sensor which is express-shipped directly from Cardiac Insight to the patient’s home, along with easy-to-follow instructions. The patient simply mails the single-use sensor to the cardiologist’s office in the included shipping envelope after wearing the sensor for the prescribed time period.

Clinicians can immediately retrieve data from the device to inform diagnoses using Cardea Solo’s smart cable and robust, proprietary algorithm-based ECG software, provided free of charge with the purchase of the [email protected] ECG Test Kit. The entire process in the office takes less than five minutes to create a complete ECG report.

“In these unprecedented times, while legacy ECG service companies employing decades-old technology are scaling back operations and decreasing services, Cardiac Insight is innovating and acting quickly to provide cardiologists and their patients with essential and easy-to-use telehealth options. As a single-use sensor, Cardea Solo affords patients, doctors and clinical staff more infection control protections with no need for cleaning or transferring devices between patients,”said Robert Odell, president and chief operating officer of Cardiac Insight. “We believe the new [email protected] program further strengthens the physician and patient relationship in a time when trust and privacy is more critical than ever, by fostering direct interactions and removing third-party data analysis vendors from the equation.”

The Cardea Solo ECG System allows physicians to reduce the diagnostic timeline of patients potentially at risk of cardiac arrhythmias from weeks to just days. These arrhythmias include atrial fibrillation (AFib). If left undiagnosed, AFib can lead to debilitating stroke, heart failure and sudden cardiac death.

The Cardea Solo [email protected] ECG Test Kit is currently available for office-based practices and hospital clinics in the U.S. and is designed to address the needs of Electrophysiologists, Cardiologists, Internal Medicine and Family Medicine physicians. Comprehensive program information and telehealth resources are available on request here.

For more information: www.cardiacinsightinc.com


Related Content

News | Atrial Fibrillation

November 10, 2022 — Biosense Webster, Inc., the global leader in cardiac arrhythmia treatment and part of Johnson & ...

Home November 10, 2022
Home
News | Atrial Fibrillation

November 10, 2022 — A national study led by UBC researchers at the Centre for Cardiovascular Innovation is shedding ...

Home November 10, 2022
Home
News | Atrial Fibrillation

October 31, 2022 — Atrial fibrillation – a form of irregular heartbeat, or arrhythmia – leads to more than 454,000 ...

Home October 31, 2022
Home
News | Atrial Fibrillation

October 26, 2022 — A new study from University of Louisville researchers in the Christina Lee Brown Envirome Institute ...

Home October 26, 2022
Home
News | Atrial Fibrillation

September 14, 2022 — In recognition of Atrial Fibrillation (AFib) Awareness Month, Biosense Webster, Inc., part of ...

Home September 14, 2022
Home
News | Atrial Fibrillation

September 9, 2 022 — A large-scale international study led by Mount Sinai has yielded the first risk score that can help ...

Home September 09, 2022
Home
News | Atrial Fibrillation

August 31, 2022 — Science has long shown that men are at greater risk for developing atrial fibrillation (AFib) than ...

Home August 31, 2022
Home
News | Atrial Fibrillation

July 29, 2022 — A cohort study of persons with incident atrial fibrillation (AF) has found that AF after noncardiac ...

Home July 29, 2022
Home
News | Atrial Fibrillation

July 20, 2022 — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatments for atrial ...

Home July 20, 2022
Home
News | Atrial Fibrillation

July 6, 2022 — Atrial fibrillation (AF) is a prevalent cardiovascular condition with one of the highest rates of ...

Home July 06, 2022
Home
Subscribe Now